Early changes in islet hormone secretion in the hamster pancreatic cancer model.
The diabetic state that is seen at a high frequency in association with pancreatic cancer is characterized by elevated plasma levels of several islet hormones and by marked insulin resistance. Both the diabetic state and insulin sensitivity improve after tumor removal by sub-total pancreatectomy. Impaired glucose tolerance has also been found in the hamster pancreatic cancer model, but conflicting data regarding islet function have been reported. In order to further investigate islet function and secretion during early development of pancreatic cancer, we measured the concentrations of insulin, glucagon, somatostatin, and islet amyloid polypeptide (IAPP) in plasma, pancreatic tissue, and secretin-stimulated pancreatic juice at 12 and 27 weeks after the ductal-cell-specific carcinogen, BOP had been used to induce tumors in Syrian golden hamsters. At 12 weeks after BOP, plasma glucagon levels were significantly increased. An exaggerated plasma-glucose response and concomitant hyperinsulinemia were observed at 27 but not 12 weeks after BOP. Plasma IAPP concentrations, but not glucagon or somatostatin, were elevated at 27 weeks. Tissue concentrations of IAPP were substantially reduced in BOP-treated hamsters at 27 weeks. No differences in hormone concentrations were seen in pancreatic juice from the two groups at either of the two time points investigated. The study showed that islet hormone changes accompany the early development of pancreatic tumors in the hamster pancreatic model. The hormone changes and apparent insulin resistance resemble the metabolic changes found in humans with pancreatic cancer.
Permert
J
J
Department of Biomedical Sciences, Creighton University School of Medicine, Omaha, Nebraska, USA. johan.permert@karo.ki.se
Herrington
M
M
Kazakoff
K
K
Pour
P M
PM
Adrian
T E
TE
D000230:Adenocarcinoma / Q000139:chemically induced / Q000378:metabolism* / Q000473:pathology; D000682:Amyloid / Q000032:analysis / Q000378:metabolism*; D000818:Animals; D002273:Carcinogens / Q000633:toxicity; D006224:Cricetinae; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism; D004195:Disease Models, Animal; D005934:Glucagon / Q000032:analysis / Q000378:metabolism; D005951:Glucose Tolerance Test; D007328:Insulin / Q000032:analysis / Q000378:metabolism*; D007333:Insulin Resistance; D000078790:Insulin Secretion; D058228:Islet Amyloid Polypeptide; D007515:Islets of Langerhans / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008647:Mesocricetus; D009602:Nitrosamines / Q000633:toxicity; D010189:Pancreatic Juice / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism; D010190:Pancreatic Neoplasms / Q000139:chemically induced / Q000378:metabolism* / Q000473:pathology; D013004:Somatostatin / Q000032:analysis / Q000378:metabolism
D000682:Amyloid; D002273:Carcinogens; D007328:Insulin; D058228:Islet Amyloid Polypeptide; D009602:Nitrosamines; D013004:Somatostatin; C013622:nitrosobis(2-oxopropyl)amine; D005934:Glucagon